MP38-05 TARGETED LIQUID CHROMATOGRAPHY MASS SPECTROMETRY QUANTIFICATION OF EXCRETED URINARY ESTROGENS AMONG POSTMENOPAUSAL WOMEN USING DIFFERENT ESTROGEN HORMONE THERAPY MODALITIES

Abstract

You have accessJournal of UrologyCME1 May 2022MP38-05 TARGETED LIQUID CHROMATOGRAPHY MASS SPECTROMETRY QUANTIFICATION OF EXCRETED URINARY ESTROGENS AMONG POSTMENOPAUSAL WOMEN USING DIFFERENT ESTROGEN HORMONE THERAPY MODALITIES Michael L. Neugent, Neha Hulyalkar, Vladimir Shulaev, Philippe E. Zimmern, and Nicole J. De Nisco Michael L. NeugentMichael L. Neugent More articles by this author , Neha HulyalkarNeha Hulyalkar More articles by this author , Vladimir ShulaevVladimir Shulaev More articles by this author , Philippe E. ZimmernPhilippe E. Zimmern More articles by this author , and Nicole J. De NiscoNicole J. De Nisco More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002592.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Estrogen hormone therapy (EHT) is commonly used among postmenopausal women to treat symptoms of menopause. EHT can be administered via multiple modalities including oral (oEHT), transdermal patch (pEHT), and vaginal (vEHT). To date, there is little quantitative literature comparing the modalities of EHT and their respective excreted metabolites. Quantifying excreted estrogens to assess EHT dosage, compliance, or metabolism can be challenging due to the chemical nature of estrogens and their metabolites. The goal of this work was to develop and implement a robust, sensitive liquid chromatography mass spectrometry (LC-MS)-based targeted assay for the detection of excreted urinary estrogen conjugates at the picomolar range using a minimal volume of urine. METHODS: We used a strictly curated, controlled cohort of postmenopausal women (n=50) who passed a set of exclusion criteria for an ongoing study of recurrent UTI (rUTI) but were not currently experiencing infection at the time of urine donation. Clean-catch mid-stream urine was collected, estrogens were extracted from urine via solid phase extraction, and analyzed by a sensitive, targeted LC-MS. RESULTS: In this study we generated a sensitive, targeted LC-MS assay for the quantification of urinary estrogen conjugates, included the sulfates and glucuronides of Estrone (E1) and 17β-Estradiol (E2). Implementation of this assay on urine samples from a clinical cohort of postmenopausal women found that oEHT and pEHT modalities exhibited the highest levels of excreted urinary estrogen conjugates. Interestingly, we found that women using vEHT exhibited urinary estrogen concentrations that were not distinguishable from women who were not using EHT. CONCLUSIONS: These data suggest that oEHT and pEHT modalities exhibit higher concentrations of excreted urinary estrogen conjugates, which may be a proxy biomarker for systemic estrogen concentration during EHT. Source of Funding: The Welch Foundation, The Foundation for Women’s Wellness, NIH grant 1R01DK131267-01, and The University of Texas at Dallas Startup funds to NJD, The Felicia and John Cain Distinguished Chair in Women’s Health to PZ © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e619 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Michael L. Neugent More articles by this author Neha Hulyalkar More articles by this author Vladimir Shulaev More articles by this author Philippe E. Zimmern More articles by this author Nicole J. De Nisco More articles by this author Expand All Advertisement PDF DownloadLoading ...